IMAAVY

SILVER SPRING, MARYLAND, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) injection for...

Spring House, Pennsylvania, U.S. | August 24, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration...

GENEVA, Switzerland, June 26, 2026 Johnson & Johnson presented 12 new scientific abstracts at the European Academy of Neurology...

STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...

HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...

Horsham, Pennsylvania, USA – April 22, 2026 In a major advancement for autoimmune neurology, Johnson & Johnson has reported...

February 24, 2026 – Spring House, Pennsylvania, USA Johnson & Johnson has announced the submission of a supplemental Biologics...